- |||||||||| letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Evaluation of IM Letrozole ISM (clinicaltrials.gov) - Jan 22, 2019 P1, N=120, Recruiting, Trial completion date: Sep 2019 --> Jul 2020 | Trial primary completion date: Apr 2019 --> Jul 2020
- |||||||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Enrollment closed, Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Dec 5, 2018 P1, N=256, Active, not recruiting, We desperately need an effective adjuvant therapy for women with early stage uLMS. Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2019 --> Nov 2019
- |||||||||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: Palbociclib and FES PET (clinicaltrials.gov) - Dec 5, 2018 P2, N=15, Active, not recruiting, Active, not recruiting --> Completed Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
- |||||||||| Trial completion date, Trial primary completion date: Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients (clinicaltrials.gov) - Nov 23, 2018
P3, N=107, Recruiting, An alternative schedule of extended adjuvant endocrine therapy with letrozole, including intermittent administration, might be feasible and the results of the SOLE trial support the safety of temporary treatment breaks in selected patients who might require them. Trial completion date: Mar 2018 --> Jan 2019 | Trial primary completion date: Mar 2018 --> Dec 2018
- |||||||||| Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - Nov 7, 2018 P1/2, N=40, Recruiting, Recruiting --> Active, not recruiting | Initiation date: Nov 2016 --> Sep 2012 Trial completion date: Oct 2018 --> Oct 2020 | Trial primary completion date: Oct 2018 --> Oct 2019
- |||||||||| NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects (clinicaltrials.gov) - Oct 26, 2018 P1, N=60, Recruiting, ET + CDK4/6 or mTOR inhibitors are likely safe and effective in older patients with HR+, HER2- advanced breast cancer. Trial completion date: Sep 2018 --> Dec 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- |||||||||| Trial completion date, Trial primary completion date, Combination therapy, Metastases: BOLERO-5: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (clinicaltrials.gov) - Oct 24, 2018
P2, N=160, Recruiting, Trial completion date: Sep 2018 --> Dec 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Trial completion date: Mar 2021 --> Sep 2021 | Trial primary completion date: Jun 2019 --> Dec 2019
- |||||||||| letrozole / Generic mfg.
Trial completion date, Trial primary completion date: PLUM: Pilot of Letrozole for Uterine Myomas (clinicaltrials.gov) - Oct 16, 2018 P4, N=12, Completed, Not yet recruiting --> Recruiting Trial completion date: Aug 2017 --> Dec 2017 | Trial primary completion date: Aug 2017 --> Dec 2017
- |||||||||| PF-06804103 / Pfizer
Trial completion date, Trial primary completion date: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (clinicaltrials.gov) - Oct 15, 2018 P1, N=95, Recruiting, Trial completion date: Sep 2019 --> Sep 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2019 --> Sep 2018; funding unavailable Trial completion date: Feb 2021 --> Jun 2021 | Trial primary completion date: Feb 2021 --> Jun 2021
- |||||||||| everolimus / Generic mfg.
Trial completion date, Trial primary completion date: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Oct 9, 2018 P2, N=4, Active, not recruiting, Trial completion date: Feb 2021 --> Jun 2021 | Trial primary completion date: Feb 2021 --> Jun 2021 Trial completion date: Sep 2019 --> Oct 2020 | Trial primary completion date: Sep 2018 --> Oct 2019
|